Company: EDSA
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001171843-25-002028
Chunk: 68

Company: Edesa Biotech, Inc.
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 68
---
 listed or quoted; provided that, except as otherwise permitted by the 2019 Plan or an award agreement, without the consent of an affected participant, no such Board action may materially and adversely affect the rights of such participant under the terms of any previously granted and outstanding award. The Committee may waive any conditions or rights under, or amend, alter, suspend, discontinue or terminate any award theretofore granted and any award agreement relating thereto, except as otherwise provided in the 2019 Plan; provided that, except as otherwise permitted by the 2019 Plan or award agreement, without the consent of an affected participant, no such Committee or the Board action may materially and adversely affect the rights of such participant under terms of such award. In addition, without the approval of the Company’s shareholders, the Board may not alter or amend the 2019 Plan if such alteration or amendment would permit a Repricing without approval of the Company’s shareholders. The 2019 Plan will terminate at the earliest of (i) such time as no common shares remain available for issuance under the 2019 Plan, (ii) termination of the 2019 Plan by the Board, or (iii) the tenth anniversary of the effective date of the 2019 Plan. Awards outstanding upon expiration of the 2019 Plan will remain in effect until they have been exercised or terminated, or have expired.

Plan Benefits

Since the adoption of 2019 Plan through March 31, 2025 , we have granted the following stock options under the 2019 Plan to the individuals and groups listed below. In all cases, the securities underlying such stock options were our common shares. These share numbers do not take into account the effect of awards that have been cancelled or forfeited. As of the date hereof, we have granted stock options and RSUs under the 2019 Plan.

| Name and Position                                                            |     | Number of Shares 
 Subject to Stock 
 Options (1)      |            |
| Named Executive Officers                                                     |     |                  |            |
| Pardeep Nijhawan, Chief Executive Officer                                    |     |                  |     49,858 |
| Stephen Lemieux, Chief Financial Officer                                     |     |                  |     10,715 |
| Michael Brooks, President                                                    |     |                  |     46,072 |
| Executive Officer Group (2)                                                  |     |                  |    106,645 |
| Non-Employee Director Group (3)                                              |     |                  |     43